Van Lanschot Kempen Logo
Search
Van Lanschot Kempen Logo
Search
Life sciences and healthcare Van Lanschot Kempen

Life Sciences & Healthcare

One-stop shop for European life sciences companies

Life sciences & healthcare

Established as the premier, pan-European, specialist investment bank in the life sciences & healthcare sector, Van Lanschot Kempen is a trusted adviser with many repeat clients. We are your one-stop shop with top-tier international expertise and a global investor network. Our Life Sciences & Healthcare team combines in-depth sector knowledge, scientific background and business experience. For corporate clients, our goal is to ensure that all M&A and ECM transaction processes run smoothly, while achieving the best results. For investors, we offer high-quality analysis of the broadest small/mid-cap European life sciences coverage, as well as trade execution and liquidity through our specialised marketing and trading services.

    Unrivalled track record

    Consistently successful results for our clients have led to high levels of repeat business, helping Van Lanschot Kempen build outstanding credentials over the years.

    • Leading pan-European bank for ECM transactions in the life sciences & healthcare sector

    • Outstanding stock-picking track record, consistently beating healthcare indices

    • Connecting EU life sciences companies with global institutional investors

    • Experts in block trades and providing liquidity

    • More than 175 successfully executed transactions, raising over €10 billion

    • Access to both European and US capital markets

    Products and services

    Benefit from our specialist sector knowledge with solutions tailored exclusively to life sciences & healthcare.

    Mergers & acquisitions

    For both listed and private companies, with extensive experience in sell-side and buy-side.
    Right Arrow in Circle

    Corporate advisory

    Buy- and sell-side advisory for cross-border deals, strategic financial advice on capital structuring, and ECM services such as IPOs and public-to-private transactions.
    Right Arrow in Circle

    Equities trading

    Specialists in large (block) trades, orderly venture capital exits and liquidity provision.
    Right Arrow in Circle

    Debt advisory

    Independent advice on debt financing and achievement of optimal capital structures.
    Right Arrow in Circle

    Equities research

    Coverage of approx. 60 listed small/mid-cap companies, providing in-depth analyses based on our in-house sector expertise.
    Right Arrow in Circle

    Equities sales

    Bringing together global investors and European life sciences companies through roadshows, conferences and other access events.
    Right Arrow in Circle

    Equity Capital Markets

    Advice on IPOs and other equity capital markets transactions, such as follow-on capital increases, secondary offerings, share buybacks and equity-linked transactions.
    Right Arrow in Circle

    Transactions

    Great cooperation makes for excellent transactions. Our outstanding sector knowledge combined with a strong focus on understanding stocks and companies ensures we have a superior industry network and distribution power, leading to a successful track record in the market. 

    March 2025
    maat-pharma-logo
    Placement Agent
    €13 million
    PIPE
    Right Arrow in Circle
    March 2025
    transaction logo image
    Sole Financial Adviser
    €185 million
    Royalty financing agreement
    Right Arrow in Circle
    December 2024
    io biotech
    Sole Financial Adviser
    €57.5 million
    Venture debt financing
    Right Arrow in Circle
    March 2025
    Pharming logo
    Sole Financial Adviser
    SEK 725 million
    Recommended cash offer to acquire Abliva
    Right Arrow in Circle
    December 2024
    transaction logo image
    Financial Adviser to the Company
    USD 479 million
    US Public Offering
    Right Arrow in Circle
    December 2024
    transaction logo image
    Sole Financial Adviser
    €20 million
    Venture debt financing

    Right Arrow in Circle
    June 2024
    zealand
    Lead Manager
    USD 1.0 billion
    Accelerated Bookbuild Offering
    Right Arrow in Circle
    May 2024
    merus
    Lead Manager
    USD 460 million
    US Public Offering
    Right Arrow in Circle
    April 2024
    Pharming logo
    Sole Financial Adviser
    New issue €100 million & repurchase €123 million
    Convertible bond issue and repurchase
    Right Arrow in Circle
    February 2024
    Autolus logo
    Co-Manager
    USD 350 million
    US Offering
    Right Arrow in Circle
    January 2024
    galapagos
    Financial Adviser
    €170 million
    Sale of Jyseleca business to Alfasigma

    Right Arrow in Circle
    December 2023
    zealand
    Sole Financial Adviser
    €90 million
    Venture debt financing
    Right Arrow in Circle
    October 2023
    Cantargia logo
    Joint Global Coordinator                            & Joint Bookrunner
    SEK 59.3 million
    Directed Share Issue
    Right Arrow in Circle
    October 2023
    transaction logo image
    Joint Global Coordinator                        & Joint Lead Bookrunner
    NOK 505 million
    Accelerated Bookbuild Offering
    Right Arrow in Circle
    October 2023
    synact pharma
    Sole Financial Adviser
    SEK 120 million
    Structured Equity with Warrants
    Right Arrow in Circle
    August 2023
    merus
    Lead manager
    USD 173 million
    Capital Increase
    Right Arrow in Circle
    July 2023
    argenx
    Manager
    USD 1.3 billion
    Capital Increase
    Right Arrow in Circle
    June 2023
    vicore pharma
    Joint Bookrunner
    SEK 500 million
    Capital increase
    Right Arrow in Circle
    June 2023
    transaction logo image
    Financial Adviser
    USD 182 million
    Secondary sell-down
    Right Arrow in Circle
    May 2023
    transaction logo image
    Joint Global Coordinator & Joint Bookrunner
    €25 million
    Accelerated Bookbuild Offering
    Right Arrow in Circle
    April 2023
    sequana medical
    Joint Global Coordinator & Joint Bookrunner
    € 15.8 million
    Accelerated Bookbuild Offering
    Right Arrow in Circle
    April 2023
    zealand
    Lead Manager
    DKK 1.5 billion
    Accelerated Bookbuild Offering
    Right Arrow in Circle
    March 2023
    transaction logo image
    Financial Advisor, Capital Markets Advisor & Placement Agent
    USD 220 million
    PIPE USD 91 million
    Right Arrow in Circle
    Feb 2023
    curevac
    Lead Manager
    USD 250 million
    US Public Offering
    Right Arrow in Circle
    Dec 2022
    gensight
    Sole Financial Adviser
    € 12.0 million
    Convertible Note Issuance
    Right Arrow in Circle
    Dec 2022
    hansa
    Joint Global Coordinator & Joint Bookrunner
    SEK 416 million
    PIPE
    Right Arrow in Circle
    See all transactions

    Coverage list

    Curious to know more?

    Jan de Kerpel Van Lanschot Kempen

    Jan De Kerpel

    Managing Director
    Life Sciences and Healthcare
    EmailMail Jan De Kerpel
    Nadine Maalouf Van Lanschot Kempen

    Nadine Maalouf

    Managing Director
    Life Sciences & Healthcare
    EmailMail Nadine Maalouf

    Suzanne van Voorthuizen

    Head of Life Sciences Equity Research
    Emails.vanvoorthuizen@vanlanschotkempen.com